Bromfenac sodium - Generic Drug Details

What are the generic drug sources for bromfenac sodium and what is the scope of patent protection?

Bromfenac sodium is the generic ingredient in five branded drugs marketed by Bausch And Lomb Inc, Alembic, Amneal, Amring Pharms, Apotex, Chartwell Rx, Coastal Pharms, Eugia Pharma, Gland, Lupin, Rising, Sentiss, Sun Pharm, and Bausch And Lomb, and is included in nineteen NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Bromfenac sodium has twenty patent family members in thirteen countries.

Thirteen suppliers are listed for this compound.

Summary for bromfenac sodium

International Patents:	20
US Patents:	3
Tradenames:	5
Applicants:	14
NDAs:	19
Finished Product Suppliers / Packagers:	13
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	7
Drug Prices:	Drug price trends for bromfenac sodium
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for bromfenac sodium
What excipients (inactive ingredients) are in bromfenac sodium?	bromfenac sodium excipients list
DailyMed Link:	bromfenac sodium at DailyMed

See drug prices for bromfenac sodium

Recent Clinical Trials for bromfenac sodium

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Seoul National University Hospital	Phase 2
Bausch & Lomb Incorporated	PHASE4
Retina Research Institute, LLC	PHASE4

See all bromfenac sodium clinical trials

Pharmacology for bromfenac sodium

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for bromfenac sodium

S01BC	Antiinflammatory agents, non-steroids
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for BROMFENAC SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BROMSITE	Ophthalmic Solution	bromfenac sodium	0.075%	206911	1	2017-10-25
PROLENSA	Ophthalmic Solution	bromfenac sodium	0.07%	203168	1	2013-07-26

US Patents and Regulatory Information for bromfenac sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amring Pharms	BROMFENAC SODIUM	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	202030-001	Jan 9, 2013		DISCN	No	No
Lupin	BROMFENAC SODIUM	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	206027-001	Nov 22, 2023	AB	RX	No	No
Apotex	BROMFENAC SODIUM	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	202435-001	Jun 19, 2014		DISCN	No	No
Sentiss	BROMFENAC SODIUM	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203395-001	Jan 22, 2014	AT2	RX	No	No
Coastal Pharms	BROMFENAC SODIUM	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	201211-001	May 11, 2011		DISCN	No	No
Bausch And Lomb	PROLENSA	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203168-001	Apr 5, 2013	AB	RX	Yes	Yes	10,085,958		Y
Alembic	BROMFENAC SODIUM	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	214340-001	Jul 8, 2024	AB	RX	No	No

Expired US Patents for bromfenac sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb	PROLENSA	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203168-001	Apr 5, 2013	9,144,609
Bausch And Lomb Inc	XIBROM	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	021664-001	Mar 24, 2005	4,910,225
Bausch And Lomb	PROLENSA	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203168-001	Apr 5, 2013	8,129,431
Bausch And Lomb	PROLENSA	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203168-001	Apr 5, 2013	9,561,277
Bausch And Lomb	PROLENSA	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203168-001	Apr 5, 2013	8,754,131
Bausch And Lomb	PROLENSA	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203168-001	Apr 5, 2013	8,669,290
Bausch And Lomb	PROLENSA	bromfenac sodium	SOLUTION/DROPS;OPHTHALMIC	203168-001	Apr 5, 2013	8,871,813

International Patents for bromfenac sodium

Country	Patent Number	Title	Estimated Expiration
Canada	2852995	COMPOSITION OPHTALMIQUE QUI CONTIENT DU BROMFENAC PRESENTANT UNE BIODISPONIBILITE ACCRUE (OCULAR COMPOSITION CONTAINING BROMFENAC WITH INCREASED BIOAVAILABILITY)
European Patent Office	2765988	COMPOSITION CONTENANT BROMOFENAC À L'ADMINISTRATION À VOIE OCULAIRE AVEC UNE BIODISPONIBILITÉ AUGMENTÉ (OCULAR COMPOSITION CONTAINING BROMFENAC WITH INCREASED BIOAVAILABILITY)
European Patent Office	4491170	COMPOSITION CONTENANT BROMOFENAC À L'ADMINISTRATION PAR VOIE OCULAIRE AVEC UNE BIODISPONIBILITÉ AUGMENTÉ (OCULAR COMPOSITION CONTAINING BROMFENAC WITH INCREASED BIOAVAILABILITY)
Spain	2992712
Finland	2765988
Croatia	P20241509
Hungary	E069597

Supplementary Protection Certificates for bromfenac sodium

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1586316	2011C/027	Belgium		PRODUCT NAME: BROMFENAC; AUTHORISATION NUMBER AND DATE: EU/1/11/692/001 20110523
1586316	132011901975261	Italy		PRODUCT NAME: BROMFENAC(YELLOX); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/692/001, 20110518
1586316	11C0031	France		PRODUCT NAME: BROMFENAC, SES SELS OU HYDRATES PHARMACOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/692/001 20110518
1586316	SPC/GB11/054	United Kingdom		PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
1586316	C 2011 004	Romania		PRODUCT NAME: BROMFENAC, SARURILE SI HIDRATII SAI ACCEPTABILI FARMACEUTICACID 2-[2-AMINO-3-(4-BROMOBENZOIL)FENILACETIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/692/001; DATE OF NATIONAL AUTHORISATION: 20110518; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/692/001; DATE OF FIRST AUTHORISATION IN EEA: 20110518
1586316	C300494	Netherlands		PRODUCT NAME: BROMFENAC, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF HYDRAAT; REGISTRATION NO/DATE: EU/1/11/692/001 20110518
1586316	122011100019	Germany		PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518

Bromfenac Sodium Market Dynamics and Financial Trajectory: Pricing, Share, Patent/Generic Risk, and Revenue Outlook

Last updated: May 13, 2026

Bromfenac sodium’s commercial trajectory is shaped by ophthalmic cyclic-NSAID competition, high generics penetration in many markets, and ongoing retailer and payer price pressure. In the US, revenue is driven by branded launches and refill volumes for ophthalmic indications (notably post-cataract pain/inflammation and related ocular inflammation uses where approved). Patent exclusivity is limited by short-lived formulation and use protection compared with blockbuster chronic therapies, making generic substitution the dominant long-run driver in most geographies.

What is the current market size for bromfenac sodium (ophthalmic) and how does it grow?

Bromfenac sodium is a niche ophthalmology asset rather than a high-volume systemic blockbuster. Demand correlates with cataract procedure volumes, ophthalmic surgery incidence, and post-operative prescription patterns for NSAIDs to control pain and inflammation.

Key market demand drivers

• Cataract surgery throughput: procedure volumes determine “base” prescriptions for peri-operative ocular meds.
• Switching and substitution: cyclic NSAIDs (including ketorolac, nepafenac, bromfenac alternatives) compete for the same post-operative category.
• Channel structure: branded and authorized generics trade off against independent generics in retail and hospital channels depending on market.
• Reimbursement and tendering: many ophthalmic products face price-down cycles after generic entry, especially in government and payer formularies.

Commercial implication

• Growth is largely procedural volume-linked with limited incremental demand unless a branded product wins formulary positioning or expands to higher-frequency dosing regimens where clinically accepted.

How do pricing and reimbursement dynamics affect bromfenac sodium revenue?

Pricing pressure is the central financial variable once generics gain access.

Price formation dynamics

• Post-generic erosion: branded ophthalmic NSAIDs typically face sharp net price declines after generic entry, with durable declines driven by pharmacy benefit substitution rules.
• Tender-based pricing: in countries with national procurement, lowest net price tends to win recurring contracts.
• Mix shift to fewer competitors: repeated interchange among NSAIDs can consolidate market share to the lowest cost or the formulary-preferred agent, depending on country.

Financial effect

• Gross-to-net compresses quickly after generic approvals, reducing both branded revenue and margin even if unit volume stabilizes.

Which companies currently sell bromfenac sodium products and what share pressures exist?

Bromfenac sodium is sold by branded product holders in some markets and by multiple generic manufacturers after patent windows close. Competitive share pressure comes from:

• Other ophthalmic NSAIDs (ketorolac, nepafenac, diclofenac) that are often treated as interchangeable by prescribers depending on formulation and dosing frequency.
• Authorized generics and narrow therapeutic class substitution under formulary mechanisms.

Commercial implication

• Market share is contestable on (1) dosing convenience (once-daily vs multiple-daily regimens for comparators), (2) bottle size and treatment course fit, and (3) formulary tier placement.

How do patent estates and exclusivity windows drive financial trajectory for bromfenac sodium?

Bromfenac sodium’s financial profile tends to move in “regime shifts”:

• Pre-expiration: branded or protected product pricing power.
• Post-expiration: generic inflow causes revenue contraction and margin normalization.

Typical protection stack in ophthalmics

• Composition-of-matter or early salts/active protection (often expired or near expiration for older NSAIDs).
• Formulation protection (buffering, surfactant system, viscosity, preservatives).
• Method-of-use protection tied to dosing regimens and indication-specific claims.
• Packaging and manufacturing-related IP, where still active.

Financial implication

• If remaining claims are formulation or method-of-use with narrow scope, generic entry can still proceed with “design around” formulations, leading to faster revenue declines than in molecule-level exclusivity.

When does bromfenac sodium lose exclusivity in the US and key EU markets?

A precise exclusivity calendar requires Orange Book and jurisdiction-specific patent term data tied to each marketed product and NDA/ANDA. With that dataset not provided here, an exact date-by-date exclusivity schedule cannot be stated.

What can be concluded from standard ophthalmic timelines

• The dominant revenue inflection generally occurs around the end of listed US patent terms or exclusivity-linked entry barriers, after which branded sales fall sharply and then flatten at lower levels dominated by generics.

What Orange Book status applies to bromfenac sodium products in the US?

Orange Book status is product-specific (each NDA/strength/dosage form can have different patent lists). Without the NDA number(s) and strength(s), Orange Book “listed patents” and “expires/remaining” status cannot be accurately enumerated.

How strong is the patent estate for bromfenac sodium and what patents matter most?

Bromfenac sodium is commonly exposed to generic competition because:

• Ophthalmic NSAIDs often have older foundational chemical protection that has largely run out.
• Remaining value is frequently concentrated in secondary patents on formulation and regimen.

Patent strength pattern in ophthalmics

• Narrow claim scope on excipients or dosing interval can still delay entry but rarely prevents generic penetration for long once claims are challenged successfully.
• If method-of-use claims map tightly to approved labeling, they can constrain “at-launch” generic designs, but generic manufacturers can often pursue label carve-outs or use-design strategies depending on local regulatory frameworks.

How do Paragraph IV ANDA challenges affect bromfenac sodium financials?

Paragraph IV challenges are a key driver of revenue disruption in the US because they can accelerate generic launch by triggering litigation and potential entry after FDA approval and settlement terms.

Financial effect when Paragraph IV is filed

• Short-term: branded revenue protection if litigation results in “stay” settlements.
• Medium-term: revenue drop on generic launch even if litigation continues, because branded prescriptions shift to the lower-cost alternative.
• Post-launch: unit volume may remain stable as class prescriptions persist, but branded net revenue and margins decline.

What patent litigation and settlement history affects bromfenac sodium commercialization?

A product-level litigation and settlement map depends on:

• specific NDA(s)/ANDA(s),
• litigated patent numbers,
• court docket and settlement dates,
• whether settlements included 180-day exclusivity triggers.

Without those specifics, litigation timelines cannot be reliably reported here.

Does bromfenac sodium face biosimilar-type competition?

No. Bromfenac sodium is a small-molecule drug. The biosimilar framework does not apply.

What formulations of bromfenac sodium are sold (solutions, strengths, dosing schedules) and how do they affect profitability?

Ophthalmic bromfenac sodium is typically marketed as an ophthalmic solution. Profitability depends on:

• Strength and packaging that match dosing course duration.
• Preservative system and patient comfort profile.
• Shelf stability and manufacturing yield.

Commercial implication

• Products with dosing simplicity (e.g., once-daily regimens where labeling supports it) often hold better prescription persistence against competing cyclic NSAIDs, sustaining branded revenue longer even after price erosion begins.

How does bromfenac sodium compete versus ketorolac, nepafenac, and diclofenac in post-cataract inflammation?

Competitive positioning for post-operative ocular inflammation pain control hinges on:

• Clinical outcomes viewed by prescribers (pain scores and resolution timing).
• Safety perceptions, including corneal considerations.
• Dosing convenience and patient adherence.

Expected market behavior

• When multiple NSAIDs are clinically acceptable, formulary preference tends to favor the lowest-cost agent unless a branded manufacturer sustains a superior value argument through contracting or dosing preference.

What generic entry risks exist for bromfenac sodium in the US?

Generic entry risk is high because:

• Many ophthalmic NSAIDs share substitution dynamics.
• Composition and formulation changes can be engineered to avoid infringement while still meeting bioequivalence and labeling requirements.

Financial implication

• Branded sales typically convert quickly from branded to generic once entry barriers lapse, with revenue flattening at a lower baseline.

What manufacturing and IP barriers can delay bromfenac sodium generic launches?

Manufacturing and IP barriers include:

• Complex formulation requirements for sterility, particle profile, and stability.
• Patent-protected formulation elements and preservatives.
• Regulatory data exclusivity tied to new delivery or dosing.
• Litigation stays stemming from infringement arguments or settlement.

In practice, these barriers tend to delay entry rather than prevent it long-term.

How do regulatory milestones (FDA approvals, ANDA filing cycles, labeling updates) drive sales timing?

Sales timing is typically driven by:

• ANDA approval timing relative to patent expiry,
• label alignment with the reference product (including indication and dosing language),
• launch readiness including distribution contracts and pharmacy channel penetration.

For ophthalmics, even short timing shifts matter because the patient cohort is procedure-driven and seasonal formularies can lock.

What is the revenue trajectory pattern you should expect for bromfenac sodium?

A common financial trajectory for older ophthalmic small-molecules:

1. Branded peak and growth phase driven by adoption and prescriber comfort.
2. Margin compression as payers tighten net prices.
3. Inflection around generic entry as unit share migrates to generics.
4. Stabilization at lower pricing with periodic promotions or authorized generic rotations.
5. Limited upside unless a reformulation extends differentiation or labeling expansion occurs.

Key Takeaways

• Bromfenac sodium’s financial trajectory is primarily determined by ophthalmic procedure volumes and rapid net price erosion after generic entry.
• Pricing and formulary substitution are the dominant long-run variables once exclusivity protection narrows to formulation or method-of-use claims.
• In the US, revenue disruption typically tracks listed patent/Orange Book expirations and any ANDA Paragraph IV litigation or settlement-driven entry timing, but exact dates and case outcomes require product-specific patent and regulatory identifiers.
• Competition is concentrated within the class of ophthalmic NSAIDs, where dosing convenience and contracting drive durable share more than molecule-level differentiation.
• Biosimilar competition is not applicable because bromfenac sodium is a small molecule.

FAQs

1. How quickly do ophthalmic NSAIDs lose net revenue after generic entry?
2. Do once-daily bromfenac formulations outperform twice-daily ketorolac/nepafenac on prescription persistence?
3. What labeling differences between bromfenac and competing cyclic NSAIDs most affect formulary substitution?
4. How do authorized generics versus full generics change bromfenac sodium gross-to-net?
5. What procurement models in Europe most accelerate price erosion for ophthalmic drops after patent expiry?

References (APA)

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/